CURRICULUM VITAE

Sheila Collins

OFFICE ADDRESS: 354 Preston Research Building, 2220 Pierce Avenue, Vanderbilt

University Medical Center, Nashville TN

OFFICE PHONE NO.: 615-936-5863

EDUCATION

9/73-2/79 University of Massachusetts College of Natural Sciences (Amherst, MA),

Bachelor of Science, 1979 (Zoology)

9/80-9/85 Massachusetts Institute of Technology School of Science (Cambridge,

MA), PhD 1985 (Applied Biology/Biology)

11/85-12/91 Postdoctoral Fellowship Duke University Medical Center, (Durham, NC)

LICENSURE AND CERTIFICATION Not applicable

ACADEMIC APPOINTMENTS

6/77 - 6/79 Research Assistant, Developmental Biology Laboratory

Harvard Medical School & Massachusetts General Hospital, Boston, MA

Supervisor: Dr. Jerome Gross

9/79 - 6/80 Senior Research Assistant, Division of Biology, California Institute of

Technology, Pasadena, CA

Supervisor: Dr. Tom Maniatis

1980 Summer Research Student, Divisions of Biology & Chemistry, California

Institute of Technology, Pasadena, CA

Mentors: Dr. Norman Davidson and Dr. James I. Mullins

9/80 - 9/85 Graduate Research Student, Massachusetts Institute of Technology,

Cambridge, MA

Mentor: Dr. Michael A. Marletta, thesis advisor

1984 Teaching Assistant, Massachusetts Institute of Technology, Cambridge, MA

Course title: Mechanisms of Drug Action

Mentor: Dr. R. Alan North, course instructor

1984 Teaching Assistant, Massachusetts Institute of Technology, Cambridge, MA

Course title: Mechanisms of Drug Action

Mentor: Dr. R. Alan North, course instructor

11/85 - 2/91 Postdoctoral Fellow

Howard Hughes Medical Institute, Duke University Medical Center, Durham, NC

Mentors: Dr. Robert J. Lefkowitz and Dr. Marc G. Caron

3/91 - 2/92 Assistant Research Professor

Howard Hughes Medical Institute, Duke University Medical Center, Durham, NC

2/92 - 6/94 Assistant Professor, Department of Medicine, GI Division, Duke University

Medical Center, Durham, NC

7/94 - 6/97 Assistant Professor, Department of Psychiatry and Behavioral Sciences

Assistant Professor, Department of Pharmacology

Member, The Sarah W. Stedman Center for Nutritional Studies

Duke University Medical Center, Durham, NC

7/97 - 4/04 Associate Professor, Department of Psychiatry and Behavioral Sciences

Assistant Professor, Department of Pharmacology & Cancer Biology

Member, The Sarah W. Stedman Center for Nutritional Studies

Duke University Medical Center, Durham, NC

7/03 Awarded Tenure (NB: tenure of basic science faculty in Duke Medical School

Clinical departments is uncommon and meritorious)

Duke University Medical Center, Durham, NC

4/04 - 2/07 Senior Investigator / Director, Program in Endocrine Biology

CIIT Centers for Health Research (renamed The Hamner Institutes), Research

Triangle Park, NC

2/07 - 2/10 Senior Investigator

Interim Director (for 2008), Division of Translational Biology

The Hamner Institutes for Health Sciences, Research Triangle Park, NC

2/10 - 2017 Professor, Integrative Metabolism Program, Center for Metabolic Origins of

Disease, Sanford Burnham Prebys Medical Discovery Institute, Orlando, FL

2018 – pres Professor, Cardiovascular Medicine, Dept of Medicine, Vanderbilt University

Medical Center, Nashville, TN

HOSPITAL APPOINTMENTS Not applicable

PROFESSIONAL ORGANIZATIONS

University / Institute Committees

2011- 2017 Chair, Sanford Burnham Prebys Medical Discovery Institute-Lake Nona

Institutional Animal Care and Use Committee, Orlando, FL

2010 – 2011 Vice-Chair, Sanford Burnham Medical Research Institute Lake Nona Institutional

Animal Care and Use Committee, Orlando, FL

2006 – 2009 Member, The Hamner Institutes Institutional Animal Care and Use Committee,

Research Triangle Park, NC

2007 – 2008 Member, Senior Management of the Hamner Institutes for Health Sciences,

Research Triangle Park, NC

2002 Duke University Faculty Search Committee, Dept. of Molecular Genetics &

Microbiology, Durham, NC

2002 Duke University Faculty Search Committee, Dept. of Pharmacology & Stedman

Center, Durham, NC

1996 Chancellor’s Steering Committee on Obesity Research at Duke University Medical

Center, Durham, NC

1995 – 2003 Duke University Dept. of Psychiatry representative to the Duke University

Institutional Animal Care and Use Committee, Durham, NC

PROFESSIONAL ACTIVITIES

Editorial Boards and Reviewer Assignments

2016- Board of Consulting Editors, The Journal of Clinical Investigation

2007-2016 Editorial Board, International Journal of Obesity

2003-2007 Editorial Board, Molecular Endocrinology

2003-2006 Editorial Board, Obesity Research

2003-2006 Editorial Board, Endocrinology

* regular reviewer for Diabetes, American Journal of Physiology, Nature, Cell, Cell

Metabolism, Molecular and Cellular Biology, Endocrinology, Molecular Endocrinology,

Nature Medicine, Diabetologia, Scientific Reports; Nature Communications

Grant and Review Committees

2016 - present NIH CADO Study Section, NIDDK, Standing Member from August 2016

2015 - present American Diabetes Association, Research Grant Review Committee

Member

2012 - present Keystone Symposia Board of Programming Consultants

2012 - present Keystone Symposia on Molecular and Cellular Biology, Study Group

Member

2012 Chair, Program Project Grant Review, NIDDK, NIH: Mar 27

2011 NIH Reviewer, Special Study Section ES11-002, NIEHS, NIH, Oct 24-25

2011 Chair, Program Project Grant Review, NIDDK, NIH: Mar 23

2010 NIH Reviewer, CADO Study Section, NIDDK, NIH: Oct 14-15

2009 NIH Reviewer, CADO Study Section, NIDDK, NIH: Oct 5-6

2008 -2009 Member, American Heart Association Review Committee Basic Cell and

Molecular Biology 4

2008 NIH Reviewer, Special Study Section, ZRG 1 MENR 02 M Aug 7-8

2006 Chair, Program Project Grant Review, NIDDK, NIH: Apr 24

2004-present Member, External Advisory Committee, University of Alabama,

Birmingham NIH Nutrition and Obesity Research Center

2005 Invited Participant and Panelist, Society for Women's Health Research,

Workshop on Sex and Gender Differences in Obesity and Cardiovascular

Disease, Washington, DC, Nov 2-4

2001-2002 Ad Hoc Reviewer, Endocrinology Study Section, Ctr for Scientific

Review, NIH

1999 NIH Reviewer, Special Study Section, SSS-T ZRG-NTN Obesity

1998-2001 Member, Metabolism Study Section, Center for Scientific Review, NIH

1999 NIH Reviewer, Special Emphasis Panel, ZRG1 BIO(01)

1998 NIH Reviewer, Special Emphasis Panel, ZRG2 MET(02)

1996-1998 Member, American Heart Association Molecular Signaling II National

Grant Review Committee

2016 NIH Reviewer, CADO Study Section, NIDDK, NIH: Oct 13-14

2017 NIH Reviewer, CADO Study Section, NIDDK, NIH: Feb 22-24; June 14-

15

Retained Consulting Experience

Merck Research Laboratories (Pharmacology and Obesity programs)

Novo Nordisk (Obesity and Metabolic disease programs)

Glaxo Wellcome / GSK (Respiratory, Cardiovascular and Metabolism programs)

Lederle Labs/Wyeth Pharmaceuticals (Metabolic Disease program)

Lexicon Genetics (Obesity and Metabolic disease programs)

A variety of short-term consulting activities with domestic and international Pharma and

Biotech.

Recognitions and Honors

2017 Keynote Speaker, Mid-Atlantic Pharmacology Society, Hosted by Temple

University, Philadelphia, PA Oct 26, 2017

2016 Keynote Speaker, Alberta Diabetes Institute Research Day, University of

Alberta, October 4, 2016

2013 14th Nelson Goldberg Lecturer, Dept of Biochemistry, University of

Minnesota

2008 The Hamner Senior Fellow in Endocrine Biology

2006 Invited Speaker and Participant, The 134th Nobel Symposium, Sweden

1992-1994 Mal Tyor Junior Faculty Scholar, Duke University Medical Center

1986-1990 Howard Hughes Medical Institute Postdoctoral Fellow

1979 Magna Cum Laude, Department of Zoology, University of Massachusetts

1979 Commonwealth Honor Scholar, UMass Amherst

TEACHING ACTIVITIES (former)

Medical School and University Teaching (all at Duke University on an annual basis)

PHR200B Problems in Pharmacology – case studies course in Medical Pharmacology

for 1st year Medical School students.

PTH385 Molecular Aspects of Disease – lecturer on obesity and diabetes for Pathology.

PSY223 Molecular Basis of Behavior – lecturer on monoamine receptors for

Psychology.

Duke Medical School First Year Curriculum (new as of 2005) Block I; Molecules and

Cells, Topic Lectures: Human Nutrition and Appetite Control.

PSY272S Obesity and Eating Disorders – lecturer on molecular basis of appetite.

Behavioral Neurosciences Study Program Faculty – lecturer on monoamine receptors and

their regulation.

CLINICAL TEACHING

Not applicable

RESEARCH SUPERVISION

Predoctoral Trainees:

1. Wei Wu, Endocrinology and Metabolism Program, Huashan Hospital of Fudan

University, Shanghai, China (research done in my lab); awarded PhD Jan 2017.

2. Andre R.G. Proença, Department of Physiology and Biophysics, Institute of

Biomedical Sciences, Sao Paulo University, Sao Paolo, Brazil – 6-month research

training internship; Awarded PhD, 2013.

3. Jingqi Fu, Pharmacology and Toxicology program, China Medical University, Beijing.

2008 – 2010 (co-mentor with Dr. Jingbo Pi).

4. Fatiha Moukdar, M.S., Ph.D. program, Pharmacology, Université de Montréal,

Montréal, Canada. Part of thesis work conducted at Division of Biological Sciences,

The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina,

2004-2008. Awarded PhD East Carolina Univ.

5. Tonya Martin Dixon, B.S. Ph.D. Pharmacology, Duke University, 2001.

6. Kurt J. Soeder, M.S. Pharmacology, Duke University, 2000. The 3-adrenergic

receptor activates MAP kinase in adipocytes through a Gi-dependent mechanism.

7. Sheridan K. Snedden, M.S. Pharmacology, Duke University, 1999. Strain-specific

regulation of the UCP2 gene.

8. Madlene K. Dole, M.S. Pharmacology, Duke University, 1998. Role of leptin in

controlling pulsatility in hypothalamic neurons.

9. Ambieshie Yesus, M.D. student in the Duke Medical School; ADA-supported third

year research.

Postdoctoral Trainees:

1. Ryan P. Ceddia, Ph.D. Jan 2016 - present

2. Fubiao Shi, Ph.D. Oct 2014 - present

3. Anne Bugge, Ph.D. Jul 2012 – Dec 2013

4. Eric Weatherford, Ph.D. Mar 2012-2014

5. Crystal Woodard, Ph.D. Jan 2012 – Dec 2015

6. Lea Dib, Ph.D. Sept 2011 – Nov 2013

7. Marica Bordicchia, Ph.D. Apr 2010 – Jan 2012

8. Ruidong Miao, Ph.D – July 2010 – May 2011

9. Cynthia Nagle, Ph.D. – 2008 - Feb 2010

10. Einav Yehuda-Shnaidman, Ph.D. 2007-2010

11. Dianxin Liu, Ph.D. 2006-2009

12. Haibo Wang, M.D., Ph.D. 2004-2009

13. Jingbo Pi, M.D., Ph.D. 2004-2007

14. Hui Quan, Ph.D. 2004-2006

15. Gabriel Guzman, Ph.D. 2004-2005

16. Naresh Kumar, Ph.D. 2003-2008

17. Yushi Bai, M.D., Ph.D. 2002-2006

18. Jacques Robidoux, Ph.D. 2000-2007

19. Hiroki Onuma, Ph.D. 1999-2000

20. Alexander V. Medvedev, Ph.D. 1998-2004

21. Wenhong Cao, M.S., M.D. 1998-2004

22. Shiying Wang, Ph.D. 1994-1997

23. Elizabeth M. Rohlfs, Ph.D. 1993-1994

Undergraduate Independent Study (Sanford Burnham Prebys - Lake Nona FL):

1. Liam Philben, 2013 & 2015 Summer Intern, now at University of Chicago

2. Adam Collin, 2014 Summer Intern, Florida State University – now Pharmacy

student at University of Florida

3. Alexa Roth, 2010 Summer Intern. Then obtained B.S. in Microbiology, University

of Florida 2014

Undergraduate Independent Study (Duke University):

1. Crystal Pressley 2001-2002. B.S. in Chemistry, Duke University, 2002

2. Caroline Hu, 1999-2000. B.S. in Biology, Duke University, 2000

3. Stephanie S. Ocon, 1998-1999. B.S. With Distinction in Chemistry, Duke University.

(Ph.D., Biochemistry, Stanford University).

4. Ayanna Cooper. 1997. B.S. Biochemistry, UNC, Greensboro. (Ph.D., Pharmacology,

Yale University).

5. Kevin David, 1996-1997. B.S. in Biology, Duke University. (M.D., Duke University

School of Medicine).

6. Raj Fofaria, 1995-1996. B.S. in Biology, Duke University. (M.D., Medical College of

Virginia). Also a recipient of a Duke Undergraduate Research Award grant in support

of his independent study research.

7. Allison Brucker 1994-1995. B.S. in Biology, Duke University. (M.D., Columbia

University College of Physicians and Surgeons).

OTHER SIGNIFICANT ACTIVITIES (optional) Not applicable

RESEARCH PROGRAM

Ongoing Support

R01 DK103056 (Collins) 07/01/2014 – 04/30/2018 4.2 calendar

NIH $217,500

Natriuretic peptide receptors (NPs), adipose browning, and energy expenditure

The goal of this project is to determine tissues that respond to NPs by increasing energy

expenditure and fatty acid oxidation by tissue-targeted deletion of NP receptor C in mice.

Identify promoters and enhancers of the NP receptor A and C genes using reporter constructs and

Chip-Seq. Test the hypothesis that the NP receptor A and C peptides can form heterodimers that

will impede signal transduction as a form of negative regulation and understand the mechanism.

AHA GRFW 2016 #16SFRN28620000 (Kass) 04/01/2016 – 03/31/2020 0.6 calendar

$37,673

Women and heart failure with a preserved ejection fraction: sex and menopause related

mechanisms, risk biomarkers, and new treatment strategies

In collaboration with Johns Hopkins and Northwestern Universities, the goal of this project is to

study the role of sex hormones on cGMP/PKG modulation of cardiac hypertensive and systemic

metabolic disease as it relates to heart failure in women in order to understand mechanisms

involved, more reliably identify at risk patients, and develop novel treatments by contributing

molecular and biochemical studies of human adipose tissue.

Completed Research Support

Takeda Pharmaceutical (Kelly) 12/25/2010 – 12/31/2014

Title: Obesity drug target discovery project.

Major goal: To identify novel non-CNS human targets and pathways relevant to the discovery

of biomarkers and new therapeutic targets for treatment of obesity and its complications; in

collaboration with clinical researchers at Florida Hospital Role: Collaborator

Novo-Nordisk Diabetes Innovation Award (Collins) 12/01/2012 – 07/01/2015

Title: Natriuretic peptide biologics for obesity and metabolic disease.

Major goal: To test novel natriuretic peptide formulations on human adipocytes and in animal

models to assess capacity to promote increased energy expenditure through ‘browning’ of

adipocytes expressing UCP1.

American Diabetes Association #1-13-BS-030 (Collins) 01/01/2013 – 12/31/2015

Title: Adipocyte “browning” and body fat reduction by cardiac natriuretic peptides.

Major goal: examine signaling mechanisms by which the natriuretic peptides ANP and BNP

increase the ‘browning’ program in adipose tissue, and their coordination with the SNS in this

process; transcriptional control of NPRA and NPRC receptors.

Bristol-Myers-Squibb CSRA 14-03FL (Collins) 12/03/2013 – 06/30/2016

Title: Effect of DPP‐IV inhibitors on efficacy of human BNP for fat oxidation and blood pressure

control.

Major goals: To determine if the cleavage of human BNP by DPP‐IV results in reduced

biological activity. We are particularly interested to know whether DPP‐IV inhibitors can

enhance BNP activity to increase fat metabolism, oxygen consumption and energy expenditure

in adipose tissue.

NIH R56 DK106221 (Collins) 08/01/2016 – 07/31/2017

Title: New pathway by which PKA activates mTORC1 and role in adipose browning.

Major goal: Assess the physiological consequences of specific inactivation of the PKA-

mTORC1 pathway we have discovered using tissue-specific knock-in mice containing a

mutation of the PKA site in Raptor that abrogates activity of mTORC1 through PKA., but not

through the insulin signaling pathway. Studies include adipocyte cell lines expressing this

mutation by CRISPR-Cas9.

Pending Research Support

R01 DK116625 (Collins) 12/01/2017 – 11/30/2022 4.2 calendar

NIH $338,878

Dissecting PKA activation of mTORC1 and its function in adipose tissue

The goal of this project is to establish the contribution of the mTORC1 complex and role of

Raptor in particular in adipose tissue and βAR and PKA-dependent generation of energy burning

UCP1-expressing ‘beige’ adiposcytes in white fat depots. The goal is to understand the

mechanics of this pathway to ultimately find molecules that can selectively increase fat burning

to fight obesity.

PUBLICATIONS AND PRESENTATIONS

Peer-Reviewed Publications

1. Collins S, Marletta MA (1984). Carcinogen binding proteins: high affinity binding sites for

Benzo[a]pyrene in mouse liver distinct from the Ah receptor. Mol Pharmacol 26: 353-359.

2. Collins S, Altman JD, Marletta MA (1985). Development of an affinity chromatography

resin for the purification of carcinogen binding proteins from mouse liver. Biochem

Biophysl Res Commun 129: 155-162.

3. Collins S, Marletta MA (1986). Purification of a Benzo[a]pyrene binding protein by affinity

chromatography and photoaffinity labeling. Biochemistry 25: 4322-4329.

4. Bouvier M, Hnatowich M, Collins S, Kobilka BK, DeBlasi A, Lefkowitz RJ Caron MG

(1987). Expression of a human cDNA encoding the β-adrenergic receptor in chinese hamster

fibroblasts (CHW): Functionality and regulation of the expressed receptors. Mol Pharmacol

33: 133-139.

5. Kobilka BK, Frielle T, Collins S, Yang-Feng T, Kobilka TS, Francke U, Lefkowitz RJ,

Caron, MG (1987). An intronless gene encoding a potential member of the family of

receptors coupled to guanine nucleotide regulatory proteins. Nature 329: 75-79.

6. Frielle T, Collins S, Daniel KW, Caron MG, Lefkowitz RJ, Kobilka BK (1987). Cloning of

the cDNA for the human β1-adrenergic receptor. Proc Natl Acad Sci USA 84: 7920-7924.

7. Collins S, Quarmby French FS, Lefkowitz RJ, Caron MG (1988). Regulation of the β2-

adrenergic receptor and its mRNA in the rat ventral prostate by testosterone. FEBS Letters

233: 173-176.

8. Collins S, Caron MG, Lefkowitz RJ (1989). β2-adrenergic receptors in hamster smooth muscle

cells are transcriptionally regulated by glucocorticoids. J Biol Chem 263: 9067-9070.

9. Bouvier M., Collins S, de Blasi A, Campbell P, Irons G, MacGregor C, Caron MG,

Lefkowitz RJ (1989). Two distinct pathways for cAMP mediated down regulation of the β2-

adrenergic receptor: Phosphorylation of the receptor and regulation of its mRNA level. J

Biol Chem 264: 16786-16792.

10. Collins S, Bouvier M, Bolanowski MA, Caron MG, Lefkowitz RJ (1989). Cyclic AMP

stimulates transcription of the β2-adrenergic receptor gene in response to short term agonist

exposure. Proc Natl Acad Sci USA 86: 4853-4857.

11. Lorenz W, Lomasney JW, Collins S, Regan JW, Caron MG, Lefkowitz RJ (1990).

Expression of three alpha-2 adrenergic receptor subtypes in rat tissues: implications for

alpha-2 receptor classification. Mol Pharmacol 38: 599-603.

12. Izzo N, Seidman CE, Collins S, Colucci WS (1990). β1-Adrenergic receptor mRNA level is

regulated by norepinephrine in rabbit aortic smooth muscle cells. Proc Natl Acad Sci USA

87: 6268-6271.

13. Collins S, Altschmied J, Herbsman O, Caron M G, Mellon PL, Lefkowitz RJ (1990). A

cyclic AMP response element in the β2-adrenergic receptor gene confers transcriptional

autoregulation by cAMP. J Biol Chem 265: 19330-19335.

14. Collins S, Ostrowski J, Lefkowitz RJ (1993). Cloning and sequence analysis of the human

β1-adrenergic receptor 5'-flanking promoter region. Biochim Biophys Acta 1172: 167-170.

15. Collins S, Daniel KW, Rohlfs EM, Ramkumar V, Taylor IL, Gettys TW (1994). Impaired

expression and functional activity of the β3- and β1-adrenergic receptors in adipose tissue of

congenitally obese (C57Bl/6J ob/ob) mice. Mol Endocrinol 8: 518-527.

16. Gettys TW, Rohlfs EM, Prpic V, Daniel KW, Taylor IL, Collins S (1995). Age-dependent

changes in β-adrenergic receptor subtypes and adenylyl cyclase activation in adipocytes from

Fischer 344 rats. Endocrinology 136: 2022-2032.

17. Rohlfs EM, Daniel KW, Premont RT, Kozak LP, Collins S (1995). Regulation of the

uncoupling protein gene (Ucp) by β1-, β2-, and β3-adrenergic receptor subtypes in

immortalized brown adipocyte cell lines. J Biol Chem 270: 10723-10732.

18. Wetsel WC, Liposits Z, Seidah NG, Collins S (1995). Expression of candidate pro-GnRH

processing enzymes in rat hypothalamus and an immortalized hypothalamic neuronal cell

line. Neuroendocrinology 62: 166-177.

19. Collins S, Surwit R (1996). Pharmacologic manipulation of ob expression in a dietary model

of obesity. J Biol Chem 271: 9437-9440.

20. Collins S, Kuhn C, Petro AE, Chrunyk B, Swick AG, Surwit RS (1996). Leptin and fat

regulation. Nature 380: 677.

21. Collins S, Daniel KW, Petro AE, Surwit RS (1997). Strain-specific response to 3AR agonist

treatment of diet-induced obesity in mice. Endocrinology 138: 405-413.

22. Gettys TW, Watson PM, Taylor IL, Collins S (1997). RU-486 (mifepristone) ameliorates

diabetes but does not correct deficient -adrenergic signaling in adipocytes from C57BL/6J-

ob/ob mice. Int J Obesity 21:865-873.

23. Fleury C, Neverova M, Collins S, Raimbault S, Champigny O, Levi-Meyrueis C, Bouillaud

F, Seldin MF, Surwit RS, Ricquier D, Warden CH (1997). Uncoupling protein-2: a novel

gene lined to obesity and hyperinsulinemia. Nature Genet 15: 269-272.

24. Surwit RS, Petro AE, Parekh P, Collins S (1997). Low plasma leptin in response to dietary

fat in diabetes- and obesity-prone mice. Diabetes 46: 1516-1520.

25. Aubert J, Champigny O, Saint-Marc P, Negrel R, Collins S, Ricquier D, Ailhaud G (1997).

Up-regulation of UCP-2 gene expression by PPAR agonists in preadipose and adipose cells.

Biochem Biophys Res Commun 238: 606-611.

26. Surwit RS, Wang S, Petro AE, Sanchis D, Raimbault S, Ricquier D, Collins S (1998). Diet-

induced changes in uncoupling proteins in obesity-prone and obesity-resistant strains of

mice. Proc Natl Acad Sci USA 95: 4061-4065.

27. Sanchis D, Fleury C, Chomicky N, Neverova M, Grégoire F, Rivest S, Richard D, Goubern

M, Raimbault S, Miroux B, Collins S, Warden CH, Bouillaud F and Ricquier D (1998).

BCMP1, a novel mitochondrial carrier with high expression in the central nervous system of

humans and rodents, and respiration uncoupling activity in recombinant yeast. J Biol Chem

273: 34611-34615.

28. Collins S, Daniel KW, Rohlfs EM (1999). Depressed expression of adipocyte -adrenergic

receptors is a common feature of congenital and diet-induced obesity in rodents. Int J of

Obesity 23: 669-677.

29. Soeder KJ, Snedden SK, Della Rocca GD, Luttrell LM. Collins S (1999). The 3-adrenergic

receptor activates MAP kinase in adipocytes through a Gi-dependent mechanism. J Biol

Chem 274: 12017-12022.

30. Surwit RS, Dixon TM, Petro A, Daniel KW, Collins S (2000). Diazoxide restores 3-

adrenergic receptor function in diet-induced obesity and diabetes. Endocrinology 141:3630-

3637.

31. Arsenijevic D, Onuma H, Pecqueur C, Raimbault S, Collins S, Ricquier D (2000).

Disruption of uncoupling protein-2 (UCP2) reveals a role in immunity and production of

reactive oxygen species. Nature Genet 26: 435-439.

32. Cao W, Luttrell LM, Medvedev AV, Pierce KL, Lefkowitz RJ, Collins S (2000). Direct

binding of activated c-Src to the 3-adrenergic receptor is required for MAP kinase

activation. J Biol Chem 275: 38131-38134.

33. Dixon TM, Daniel KW, Farmer SR, Collins S (2001). C/EBP is required for transcription

of the 3AR gene during adipogenesis. J Biol Chem 276: 722-728.

34. Pecqueur C, Alves-Guerra M-C, Gelly C, Levi-Meyrueis C, Couplan E, Collins S, Ricquier

D, Bouillaud F, Miroux B (2001). Uncoupling protein 2, in vivo distribution, induction upon

oxidative stress, and evidence for translational regulation. J Biol Chem 276: 8705-8712.

35. Medvedev AV, Snedden SK, Raimbault S, Ricquier D, Collins S (2001). Transcriptional

regulation of the mouse UCP2 gene: double E-box-like element is required for PPAR-

dependent activation. J Biol Chem 276: 10817-10823.

36. Surwit RS and Collins S, (2001). Revisiting lessons from the C57BL/6J mouse. Am J

Physiol 280:E825-826.

37. Cao W, Medvedev AV, Daniel KW, Collins S (2001). -Adrenergic activation of p38 MAP

kinase in adipocytes: cAMP induction of the uncoupling protein-1 (UCP1) gene requires p38

MAP kinase. J Biol Chem 276: 27077-27082.

38. Kreda S, Sumner M, Fillo S, Ribeiro C, Luo G, Xie W, Daniel KW, Shears S, Collins S,

Wetsel WC (2001). 1-Adrenergic receptors mediate LHRH secretion through

phospholipases C and A2 in immortalized hypothalamic neurons. Endocrinology 142: 4839-

4851.

39. Aubriot S, Nicolle E, Lattier M, Morel C, Cao W, Daniel KW, Collins S, Leclerc G, Faure P

(2002). New series of aryloxypropanolamines with both human 3-adrenoceptor activity and

free radical scavenging properties. Bioorg Med Chem Lett 12: 209-212.

40. Medvedev AV, Robidoux JR, Bai X, Cao W, Floering LM, Daniel KW, Collins S (2002).

Transcriptional regulation of the UCP2 gene in pancreatic INS-1 cells: dual regulation by

sterol response element and E-box binding factors. J Biol Chem 277: 42639-42644.

41. Cao W, Daniel KW, Robidoux, J, Puigserver P, Medvedev AV, Bai X, Floering LM,

Spiegelman, BM, and Collins S (2004). p38 mitogen-activated protein kinase is the central

regulator of cyclic AMP-dependent transcription of the brown fat uncoupling protein 1 gene.

Mol Cell Biol 24: 30573067.

42. Bai Y, Onuma H, Bai X, Medvedev AV, Misukonis M , Weinberg JB, Cao W, Robidoux J,

Floering LM, Daniel KW, Collins S (2005). Persistent nuclear factor-kappa B activation in

Ucp2-/- mice leads to enhanced nitric oxide and inflammatory cytokine production. J Biol

Chem 280: 19062-9.

43. Robidoux J, Cao W, Quan H, Daniel KW, Moukdar F, Bai X, Floering LM, Collins S

(2005). Selective activation of mitogen-activated protein (MAP) kinase-kinase-3 and

p38alpha MAP kinase is essential for cAMP-dependent UCP1 expression in adipocytes. Mol

Cell Biol 25: 5466-5479.

44. Cao W, Collins QF, Becker TC, Robidoux J, Lupo, Jr., EG, Xiong Y, Daniel KW, Floering

LM, Collins S (2005). p38 Mitogen-activated protein kinase plays a stimulatory role in

hepatic gluconeogenesis. J Biol Chem 280: 42731-42737.

45. Robidoux J, Kumar N, Daniel KW, Moukdar F, Medvedev AV, Cyr M, Collins S (2006).

Maximal β3-adrenergic regulation of lipolysis involves epidermal growth factor receptor-

dependent ERK1/2 activation. J Biol Chem 28: 37794-37802.

46. Kumar N, Robidoux J, Daniel K,, Floering L, Cao W, Collins S (2007). Recruitment of

vimentin to β3-adrenergic receptor and its role in ERK activation and lipolysis. J Biol Chem

282: 9244-9250.

47. Wikstrom JD, Katzman SM, Mohamed H, Twig G, Graf SA, Heart E Molina AJA, Corkey

BE, de Vargas LM, Danial NN, Collins S, Shirihai O (2007). β-cell mitochondria exhibit

membrane potential heterogeneity that can be altered by stimulatory or toxic fuel levels.

Diabetes 56: 2569-2578.

48. Pi J, Bai Y, Reece JM, Williams J, Liu, D, Freeman,ML, Fahl WE, Shugar D, Liu J, Qu W,

Collins S, Waalkes MP (2007). Molecular mechanism of human Nrf2 activation and

degradation: role of sequential phosphorylation by protein kinase CK2. Free Radic Biol Med

42: 1797-806.

49. Pi J, Bai Y, Zhang Q, Wong V, Floering LM, Daniel K, Deeny JT, Anderson ME, Corkey

BE, Collins S (2007). Reactive oxygen species as a signal in glucose-stimulated insulin

secretion. Diabetes 56: 1783-91.

50. Pi J, Zhang Q, Woods CG, Wong V, Collins S, Andersen ME (2008). Activation of Nrf2-

mediated oxidative stress response in macrophages by hypochlorous acid. Toxicol Appl

Pharmacol 226: 236-43.

51. Wang H, Zhang Y, Yehuda-Shnaidman E, Medvedev AV, Kumar N, Daniel KW, Robidoux

J, Mangelsdorf DJ, Collins S (2008). Liver X receptor is a transcriptional repressor of the

uncoupling protein-1 gene and the brown adipocyte phenotype. Mol Cell Biol 28: 2187-2200.

52. Kumar N, Liu D, Wang H, Robidoux J, Collins S (2008). Orphan nuclear receptor NOR-1

enhances cAMP-dependent Uncoupling protein-1 gene transcription. Mol Endo 22: 1057-

1064.

53. Liu H-Y, Collins QF, Xiong Y, Lupo EG, Moukdar F, Collins S, Cao W (2008). Human

neutrophil alpha-defensins inhibit hepatic gluconeogenesis through a novel signaling

pathway involving c-Src. J Biol Chem 283: 12056-12063.

54. Kumar N, Wang H, Liu D, Collins S (2009). Liver X receptor is a regulator of orphan

nuclear receptor NOR-1 gene transcription in adipocytes. Int J Obesity 33: 519-524.

55. Pi J, Bai Y, Daniel KW, Liu D, Lyght O, Edelstein D, Brownlee M, Corkey BE, Collins S

(2009). Persistent oxidative stress due to the absence of UCP2 associated with impaired

pancreatic beta-cell function. Endocrinology 140: 3040-3048 (with ‘News and Views’

highlight by R. Kulkarni).

56. Moukdar F, Robidoux J, Lyght O, Pi J, Daniel KW, Collins S (2009). Reduced antioxidant

capacity and diet-induced atherosclerosis in uncoupling protein-2-deficient mice. J Lipid Res

50: 59-70.

57. Hao Q, Hansen JB, Petersen RK, Hallenborg P, Jørgensen C, Cinti S, Larsen PJ, Steffensen

KR, Wang H, Collins S, Wang J, Gustafsson J-Å, Madsen L, Kristiansen K (2010).

ADD1/SREBP1c activates the PGC1-[alpha] promoter in brown adipocytes. Biochim

Biophys Acta - Molecular and Cell Biology of Lipids. 1801: 421-9.

58. Fu J, Woods CG, Yehuda-Shnaidman E, Zhang Q, Wong V, Collins S, Sun G, Anderson

ME, Pi J (2010). Low-level arsenic impairs glucose-stimulated insulin secretion in pancreatic

beta cells: involvement of cellular adaptive response to oxidative stress. Environ Health

Perspect 118: 864-70.

59. Pi J, Zhang Q, Fu J, Woods CG, Hou Y, Corkey BE, Collins S, Andersen ME (2010). ROS

signaling, oxidative stress and Nrf2 in pancreatic beta-cell function. Toxicol Appl Pharmacol

244: 77-83.

60. Yehuda-Shnaidman E, Buehrer B, Pi J, Kumar N, Collins S (2010). Acute stimulation of

white adipocyte respiration by PKA-induced lipolysis. Diabetes 59: 2474-2483.

61. Park D, Han CZ, Elliott MR, Kinchen JM, Trampont PC, Das S, Collins S, Lvsiak JJ, Hoehn

KL, Ravichandran KS (2011). Continued clearance of apoptotic cells critically depends on

the phagocyte Ucp2 protein. Nature 477:220-4.

62. Rogers C, Moukdar F, McGee MA, Davis B, Buehrer B, Daniel KW, Collins S, Barakat H,

Robidoux J (2012). EGF receptor (ERBB1) abundance in adipose tissue is reduced in insulin-

resistant and type 2 diabetic women. J Clin Endo Met 97:E329-E340 (accompanied by

Special Feature editorial).

63. Bordicchia M, Liu D, Amri E, Ailhaud G, Dessi-Fulgheri P, Zhang C, Takahashi N, Sarzani

R, Collins S (2012). Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat

thermogenic program in mouse and human adipocytes. J Clin Invest 122:1022-1036

(accompanied by special News and Views editorial).

64. Müller TD, Lee SJ, Jastroch M, Kabra D, Stemmer K,Aichler M, Abplanalp B,

Ananthakrishnan G, Bhardwaj N, Collins S, Divanovic S…..Moscat J, Tschöp MH (2013).

p62 links β-adrenergic input to mitochondrial function and thermogenesis. J Clin Invest

123:469–478.

65. Dib L, Bugge A, Collins S (2014). LXRα fuels fatty acid-stimulated oxygen consumption in

white adipocytes. J Lipid Res 55:247-257.

66. Mazar J, Zhao W…Collins S, Perera R (2014). The functional characterization of long

noncoding RNA SPRY4-IT1 in human melanoma cells. Oncotarget 15:8959-69.

67. Liu D, Bordicchia M, Zhang C, Fang H, Wei W, Li J-L, Guilherme A, Guntur K, Czech MP,

Collins S (2016). Activation of mTORC1 is essential for β-adrenergic stimulation of adipose

‘browning’. J Clin Invest 126 (5):1704-1716.

68. Kovacova Z, Tharp WG, Liu D, Wei W, Xie H, Collins S#, Pratley RE# (2016). Adipose

tissue natriuretic peptide receptor expression is related to insulin sensitivity in obesity and

diabetes. Obesity 24:820-828. # Co-corresponding authors.

69. Wu W*, Shi F*, Liu D, Ceddia RP, Gaffin R, Wei W, Fang H, Lewandowski ED, Collins S

(2017). Enhancing natriuretic peptide signaling in adipose tissue, but not in muscle, protects

against diet-induced obesity and insulin resistance Sci Signal Jul 25;10(489). doi:

10.1126/scisignal.aam6870. (Featured article for issue cover and accompanying Podcast).

* These two authors contributed equally.

70. Liu D, Ceddia RP, Collins S (2018). Cardiac natriuretic peptides promote adipose browning’

through mTOR complex-1. Mol Metab. 9:192-198.

71. Ragni M*, Ruocco C*, Carullo P, Ghini V, Piscitelli F, Cutignano A, Manzo E, Tedesco L,

Greco C, Rossi F, Pino A, Severi I, Liu D, Ceddia RP, Tenori L, Bifari F, Sala M, Decimo I,

Di Marzo V, Luchinat C, Collins S, Cinti S, Carruba MO, Condorelli G, Valerio A, Nisoli E

(2017). Amino acid-defined diet prevents and reverses obesity and diabetes by increasing

energy expenditure. Nature Med (in revision). * These two authors contributed equally.

72. Fischer K, …. Collins S, … Diaz-Meco M, Moscat J, Tschöp M, Müller T (2018). The

scaffold protein p62 regulates adaptive thermogenesis via modulation of Atf2 translocation

(submitted)

[For me this is a very important set of experiments that validates in spectacular fashion that

the our very first observations for an important role of p38 MAPK dependent upon PKA, and

links our previous studies on p62 to this axis for regulating brown adipocyte gene

transcription]

Select Invited Review Articles

1. Collins S, Bolanowski MA, Caron MG and Lefkowitz RJ. Genetic regulation of β-

adrenergic receptors. Ann Rev Physiol 51: 203-215, 1989.

2. Collins S, Bouvier M, Lohse MJ, Benovic JL, Caron MG and Lefkowitz RJ. Mechanisms

regulating adrenergic receptor responsiveness. Biochem Soc Trans. 18: 541-544, 1990.

3. Collins S, Lohse MJ, O'Dowd B, Caron MG, Lefkowitz RJ. Structure and regulation of G

protein-coupled receptors: the 2-adrenergic receptor as a model. In: Vitamins and

Hormones (G.D. Aurbach, Ed) Vol 46: 1-39. Academic Press, 1991.

4. Collins S, Caron MG and Lefkowitz RJ. Regulation of adrenergic receptor responsiveness

through modulation of receptor gene expression. Ann Rev Physiol 53: 497-508, 1991.

5. Collins S, Caron, M.G. and Lefkowitz RJ. From ligand binding to gene transcription: new

insights into the regulation of G protein-coupled receptors. Trends in Biochemical Sciences

17: 37-39, 1992.

6. Collins S. Molecular structure of G protein-coupled receptors and regulation of their

expression. The 2-adrenergic receptor as a model. In: Drug News and Perspectives (B.

Spilker, editor) 6: 480-487, 1993.

7. Collins S. Recent perspectives on the molecular structure and regulation of the β2-

adrenoceptor. Life Sciences 52: 2083-2091, 1993.

8. Collins S, Cao W, Soeder KJ and Snedden, SK. -adrenergic receptor signaling in

adipocytes. In: Adipocyte Biology and Hormone Signaling IOS Press. 37:51-59, 2000.

9. Collins S, Cao W, Dixon TM, Daniel KW, Onuma H, Medvedev AV. Body weight

regulation, uncoupling proteins, and energy metabolism. Nutrition and Gene Expression,

CRC Press. Editors: N Moustaid & C Berdanier pps. 261-282, 2001.

10. Collins S, and Surwit, RS. The -adrenergic receptors and the control of adipose tissue

metabolism and thermogenesis. Recent Progress in Hormone Research, The Endocrine

Society Press. Editor: AR Means. 56: 309-328, 2001.

11. Collins S, Cao W, Daniel KW, Dixon TM, Medvedev AV, Onuma H, Surwit RS.

Adrenoceptors, Uncoupling Proteins and Energy Expenditure. Experimental Biology and

Medicine 226: 982-990, 2001.

12. Robidoux J, Martin TL, Collins S. β-adrenergic receptors and regulation of energy

expenditure: a family affair. Annu Rev Pharmacol Toxicol 44: 297-323, 2004.

13. Collins S, Martin TL, Surwit RS, Robidoux J. Genetic vulnerability to diet-induced obesity

in the C57BL/6J mouse: physiological and molecular characteristics. Physiology and

Behavior 81: 243-248, 2004.

14. Collins S, Cao W, Robidoux J. Learning new tricks from old dogs: β-adrenergic receptors

teach new lessons on firing up adipose tissue metabolism. Mol Endocrinol 18: 2123-2131,

2004.

15. Pi J and Collins S. Reactive oxygen species and uncoupling protein 2 in pancreatic β-cell

function. Diabetes, Obesity and Metabolism 12 (Suppl.2): 141-148, 2010.

16. Collins S, Yehuda-Shnaidman E and Wang H. Positive and negative control of Ucp1 gene

transcription and the role of β-adrenergic signaling networks. Int J of Obesity 34: S28-S33,

2010.

17. Collins S. Can having fun protect you from obesity and its cancer risk? Pigment Cell and

Melanoma Research 25: 2-4, 2011.

18. Collins S. β-adrenergic signaling networks in adipocytes for recruiting stored fat and energy

expenditure. Frontiers in Cellular Endocrinology Vol 2 art 102 doi: 10:3389/

fedno.2011.00102. Jan 2012.

19. Collins S and Bordicchia M. Heart hormones fueling a fire in fat. Adipocyte 2: 104-108,

2013.

20. Bugge A, Dib L, Collins S. Measuring respiratory activity of adipocytes and adipose tissues

in real time. Methods in Enzymology 538: 233-247, 2014.

21. Collins S. A heart-adipose connection in the regulation of energy metabolism. Nat Rev

Endocrinol 10: 157-163, 2014.

22. Shi F and Collins S. Second messenger signaling mechanisms of the brown adipocyte

thermogenic program: an integrative perspective. Hormone Molecular Biology and Clinical

Investigation (in press), 2017.

Selected Textbook Chapters

1. Collins S, Ahima R, Kahn BB. Biology of Adipose Tissue. Joslin’s Diabetes, 14th Edition. C

Ron Kahn MD, Gordon C Weir MD, et al. (Eds.) Lippincott, Williams and Wilkins, 2005.

2. Collins S, Bai Y, Robidoux J. Adipose Tissue Development and Metabolism. Principles of

Molecular Medicine, 2nd Edition. (Chpt 51.) Marschall S Runge, MD, PHD, Cam Patterson

MD (Eds.) Humana Press, 2006.

3. Collins S, Migliorini RH, Bartness TJ. Mechanisms controlling adipose tissue metabolism by

the sympathetic nervous system: anatomical and molecular aspects. Handbook of

Contemporary Neuropharmacology. David R. Sibley (Ed.) John Wiley and Sons, 2007.

4. Collins S, Pi J, Yehuda-Shnaidman E. Uncoupling and ROS – a double-edged sword for β-

cell function?“Moderation in all things” Mitochondria in Endocrinology, edited by Pierre

Maechler, in: Best Practice & Research Clinical Endocrinology & Metabolism (Christoph

Meier, Editor-in-Chief) Volume 26, Issue 6, Pages 709-820, I1-I2 (December 2012).

Selected Invited Conference Presentations

1. Regulation of β2-Adrenergic Receptors by Cyclic AMP. Symposium on Molecular Biology

and Pathophysiology of Hormone Regulation and Actions, July 16-18, 1989. Center for High

Blood Pressure Research, University of Heidelberg, Heidelberg, Germany

2. The Role of Cyclic AMP and Other Hormones in the Regulation of β2-Adrenergic Receptor

Function. International Symposium on Genetic Factors in Hypertension, Directors' Meeting

of the SCOR in Hypertension, National Heart, Lung and Blood Institute, Sept. 25-26, 1989,

Boston, MA

3. Mechanisms Involved in Adrenergic Receptor Desensitization. Joint Colloquium on

Glycoprotein Receptors and Cell Triggering, 633rd Meeting of the Biochemical Society,

Dec. 18-20, 1989, St. Bartholomew's Hospital, London, UK

4. Multiple Pathways Regulating Adrenergic Receptor Responsiveness. Binational Science

Foundation (BSF) Joint US-Israel Workshop on Expression and Modulation of Receptors in

Normal and Diseased Tissues, sponsored by BSF and NINDS, The Weizmann Institute of

Science, Oct. 7-10, 1990, Rehovot, Israel

5. Multiple Pathways Regulating Adrenergic Receptor Responsiveness. Fidia Research

Foundation Symposium on Neurotransmitter Regulation of Gene Transcription, Satellite of

the 20th Annual Meeting of the Society for Neuroscience, Oct. 25-27, 1990, St. Louis, MO

6. Transcriptional and Post-transcriptional Pathways Regulate G Protein-Coupled Receptor

Expression. Symposium of the 5th World Congress of Biological Psychiatry:

Transcriptional Regulation of Receptors: Structure and Function, June 9-14, 1991, Florence,

Italy

7. Molecular Biology of the β-adrenergic Receptor. Satellite Symposium on β-Agonists in

Respiratory Disease, June 18-19, 1992, Amsterdam, Netherlands

8. Regulation of β2-Adrenergic Receptor Gene Transcription and Implications for Cell

Signaling. Serono International Symposium on G Protein-Associated Membrane Receptors:

Molecular Biology, Signal Transduction and Physiology, September 21-23, 1992, Geneva,

Switzerland

9. Genetic Control of β2-Adrenergic Receptors. 2nd European Pulmonary Summit, March 20-

26, 1993, Zug/Lech Arlberg, Austria

10. Molecular Biology of the β2-Adrenoceptor. Symposium on β-Adrenoceptor Agonists and the

Airways, British Pharmacological Society Spring Meeting, April 12-15, 1994, Manchester,

UK

11. Effects of 3AR Agonists to Prevent Obesity and Regulate AR Subtype Expression in

Adipocytes. The Eighth International Catecholamine Symposium, October 13-18, 1996,

Asilomar Conference Center, Pacific Grove, CA

12. Thermogenesis and Body Composition: the β3AR and the Mitochondrial UCPs. The Dr.

George W. Raiziss Biochemical Rounds, Dept. of Biochemistry and Biophysics, University

of Pennsylvania, March 31, 1998, Philadelphia, PA

13. β-Adrenergic Receptor Function in Adipocytes. IBC Industry Briefing on the Adipocyte:

Targets for Therapy, April 1, 1998, The Ritz-Carlton Tysons Corner, McLean, VA

14. β3-Adrenergic Receptors, Brown Fat and Thermogenesis. American Diabetes Association

58th Annual Scientific Sessions, June 13-16, 1998 Chicago, IL

15. Regulation of the Uncoupling Protein Genes by Nutrients and Hormones. 8th International

Congress on Obesity, August 29-Sept 3, 1998 Paris, France

16. Adrenergic Signaling in Adipocytes 27th Steenbock Symposium, Adipocyte Biology and

Hormone Signaling, June 6-9, 1999, University of Wisconsin-Madison\

17. Signaling and Regulation of Adipocyte -Adrenergic Receptors Keystone Symposium on

Molecular Control of Adipogenesis and Obesity, February 16-22, 2000, Taos, New Mexico

18. G protein coupled receptor cross-talk between the PKA and MAP kinase cascades: stories of

the adipocyte 3-adrenergic receptor ASPET-Ray Fuller Symposium: Insulin Resistance in

Diabetes and Hypertension: Syndrome X and Beyond, March 24-26, 2000 London, Ontario,

Canada

19. -adrenoceptor signaling through MAP kinase Joint meeting of the Australasian Society of

Clinical and Experimental Pharmacologists & Toxicologists and the British

Pharmacological Society, April 26-28, 2000, Melbourne, Australia

20. Adipocyte adrenergic signaling mechanisms and cross-talk Keystone Symposium on PPARs:

A Transcription Odyssey, February 4-9, 2001 Keystone, CO

21. Adipocyte adrenergic signaling mechanisms and cross-talk 9th International Catecholamine

Symposium, April 1-5, 2001 Kyoto, Japan

22. Molecular/cellular determinants of adrenergic signaling in adipocytes FASEB Summer

Conference, Obesity: advances from the gene to the environment. August 18-23, 2001

Snowmass, CO

23. Fat cell adrenoceptors and the control of adipose tissue metabolism The Gerald Friedman

Symposium 49th Annual Scientific Meeting October 28, 2001 Waldorf-Astoria Hotel, New

York, NY

24. Control of UCP1 expression by PKA/p38 MAPK and PGC1. Keystone Symposium on

Molecular Control of Adipogenesis and Obesity, January 10-16, 2002, Keystone, CO

25. Mechanisms of 3AR signaling in adipocytes and functional consequences on thermogenesis

Int. Union of Pharmacology XIVth Congress, in Symposium Obesity: Innovative Therapeutic

Approaches Based on Pharmacology Insights July 9, 2002 San Francisco, CA

26. The adipocyte ARs: signaling mechanisms and dysregulation in obesity, International

Association for the Study of Obesity (IASO) Stock Conference on Adipose Tissue: New

therapeutic targets from molecular and genetic studies. March 24-26, 2003 Lisbon, Portugal

27. Signal transduction and transcriptional pathways regulating UCPs. Workshop on Uncoupling

Proteins:Current Status and Therapeutic Prospects. Instituto Juan March, Centre for

International Meetings on Biology April 6, 2005 Madrid, Spain

28. Boston Obesity Nutrition Research Center, Adipose & Metabolic Tissue Study Group, April

19, 2005 Boston, MA

29. Obesity in the 21st Century: Genetics, environmental factors, or both? Dept. of

Biochemistry, Molecular Biology & Biophysics, University of Minnesota. April 20, 2005

Minneapolis, MN

30. Biochemical mechanisms that regulate body weight, 6th Symposium on Molecular and

Physiological Aspects of Type II Diabetes and Obesity, Nobel Forum, Wallenbergsalen,

Karolinska Institutet, Nobels väg 1, Solna. April 22, 2005 Stockholm, Sweden

31. MAPK signaling networks in adipocytes, 45th National Congress of the Sociedad Mexicana

de Nutrición y Endocrinología A.C. (Mexican Society of Nutrition and Endocrinology)

November 29, 2005 Merida, Mexico

32. Signaling networks fueling mitochondrial metabolism in fat. Diabetes Mellitus, Keystone

Symposia, January 23, 2006 Vancouver, Canada

33. Targeted disruption of Ucp2 gene causes inflammation and chronic activation of IKK in

macrophages. 66TH Scientific Sessions, American Diabetes Association, June 10, 2006

Washington, DC

34. Integration of catecholamine signaling pathways in the adipocyte. The 134th Nobel

Symposium, University of Göteborg August 8, 2006 Göteborg, Sweden

35. Kinases and their transcription targets in adipocyte cell fate. Molecular Control of

Adipogenesis and Obesity, Keystone Symposia, February 23, 2008. Banff Springs, Alberta,

Canada

36. Oxidative stress, UCP2 and β-cell function. Islet and Beta Cell Biology, Keystone Symposia,

April 6-11, 2008 Snowbird, UT

37. Uncoupling proteins, ROS and β-cell function. Membrane Transport Proteins, Gordon

Research Conference, July 20-25, 2008, Il Ciocco, Italy

38. Mitochondrial reactive oxygen species and glucose-stimulated insulin secretion. Role of

Oxidative Stress in Aging and Age-Related Diseases, Gordon Research Conference, March

2009, Il Ciocco, Italy

39. A good side of ROS as a signal in pancreatic β-cells. Symposium presentation at American

Diabetes Association Annual Scientific Sessions, June 2009, New Orleans, LA

40. Signaling networks regulating Ucp1 and brown fat thermogenesis The 12th Annual

International Symposium, Merck-Frosst /CIRH Research Chair in Obesity: Rediscovering

Brown Adipose Tissue November 6, 2009, Auberge Saint-Antoine, Quebec, Canada

41. Role of p38 MAP kinase in conveying β-adrenergic activation of brown fat thermogenesis.

Brown Adipose Tissue and Human Obesity – An ICO 2010 Pre-congress meeting, Stockholm

University, July 2010, Stockholm, Germany

42. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program

in mouse and human adipocytes. Genetic and Molecular Basis of Obesity and Body Weight

Regulation, Keystone Symposia, February 2012, Santa Fe, MN

43. Cardiac natriuretic peptide receptor signaling promotes ‘brown’ adipocyte expansion and

energy expenditure. BENZON SYMPOSIUM No. 58 Adipose Tissue in Health and Disease,

August 27-30, 2012, Copenhagen, Denmark

44. Cyclic nucleotides and energy balance. University of Bonn Institute of Pharmacology and

Toxicology Seminar Series, December 17, 2012, Bonn, Germany

45. Converging cyclic nucleotide second messengers regulate fat metabolism. The 2013 Nelson

D. Goldberg Lecture, University of Minnesota, March 6, 2013, Minneapolis, MN

46. Guest Lecturer, University of Copenhagen Faculty Club, April 18, 2013, Copenhagen,

Denmark

47. Turing White Fat to Beige and Brown. Copenhagen Obesity Symposium, April 19-21, 2013,

Gentofte, Denmark

48. Natriuretic peptides and fat metabolism. 6th International Conference on cGMP, June 28-30,

2013, Erfurt, Germany

49. Signaling Networks "Britening" Adipocytes: Some Old, Some New. Keystone Symposia:

Lipid Pathways in Biology and Disease. Royal Dublin Society, March 19-24, 2014, Dublin,

Ireland

50. Heart-Adipose Connection for Metabolism and Energy Expenditure. Cardiovascular

Medicine Grand Rounds Distinguished Speaker, University of Louisville Dept. of Medicine,

and Institute for Diabetes Center, April 16, 2014, Louisville, KY

51. Adipose Tissue Shades of Brown and How We Get There. The 15th Annual International

Symposium, Merck-Frosst /CIRH Research Chair in Obesity: G Protein Coupled Receptors

in Energy Expenditure, November 9, 2014, Auberge Saint-Antoine, Quebec, Canada

52. Mechanisms Increasing Mitochondria and Adipose Browning for Energy Expenditure.

International Diabetes Federation World Diabetes Congress 2015 Nov 30 – Dec 4, 2015,

Vancouver, Canada

53. Integrating Signaling Mechanisms for Adipose ‘Browning’. Obesity and Adipose Tissue

Biology, Keystone Symposia, February 2016, Banff, Alberta, Canada

54. Evolving Role of Adipose Tissue: From Storage Locker to Metabolic Integrator. University

of Alberta, 2016 Alberta Diabetes Institute Research Day – Keynote Speaker, October 2-5,

2016, Edmonton, Alberta, Canada

55. Regulators of Brown and ‘Beige’ Adipose Metabolism and Energy Expenditure: New Twists

on an Old Story. The Scripps Research Institute, November 2-4, 2016, Jupiter, FL

56. Signaling Mechanisms Controlling White and Brown Fat Metabolism and Energy

Expenditure. University of South Florida, January 29-31, 2017, Tampa, FL

57. Signaling Mechanisms Controlling White and Brown Fat Metabolism and Energy

Expenditure. University of California, Berkeley, February 13-17, 2017, San Francisco, CA

58. Natriuretic Peptides in Fuel Metabolism and Insulin Sensitivity: Studies from Mouse Models

and Humans. 60th German Conference on Endocrinology, March 15-17, 2017, Würzburg,

Germany

59. Role of PKA-activated mTOR in Fat Cell Metabolism and Thermogenesis. 13th Insulin

Receptor and Insulin Action Meeting, April 18-22, 2017, Nice, France

60. Integrating New and Old Hormonal Signaling Mechanisms Regulating Brown Adipose

Function. International Conference on Translational and Therapeutic Perspectives of Brown

Adipose, May 2-5, 2017, Copenhagen, Denmark

61. Signaling Mechanisms Controlling White and Brown Fat Metabolism and Energy

Expenditure. EMBO Workshop on Brown Adipose Tissue, May 23-28, 2017, Sitges,

Barcelona, Spain

62. Signaling Mechanisms Controlling White and Brown Fat Metabolism and Energy

Expenditure. Helmholtz-Nature Medicine Diabetes Conference, September 17-19, 2017,

Munich, Germany

63. Receptor Signaling in Adipocytes for Energy Expenditure and Metabolic Health. Mid-

Atlantic Pharmacology Society Symposium, October 25-27, 2017, Philadelphia, PA

64. Cardiometabolic Communication Controlling White and Brown Fat Metabolism and Energy

Expenditure. Albert Einstein Diabetes Center Conference, November 2-3, 2017, Bronx, NY

65. Signaling Mechanisms Controlling White and Brown Adipocyte Metabolism and Energy

Expenditure. University of Texas Health Science Center – San Antonio, November 16-17,

2017, San Antonio, TX

66. Receptor Systems and Signaling Mechanisms in White and Brown Adipocytes. Bioenergetic

and Metabolic Disease, Keystone Symposia, January 2018, Keystone CO